Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plexxikon, Roche Near Catalyst For BRAF Inhibitor In Melanoma

This article was originally published in The Pink Sheet Daily

Executive Summary

As its melanoma drug advances in the clinic, Plexxikon obtains rights to co-promote it in the U.S.

You may also be interested in...



Plexxikon Wins Tafinlar Patent Dispute Case Against Novartis

The Daiichi Sankyo affiliate successfully argued that Novartis willfully infringed two patents covering its discoveries in the BRAF inhibitor drug class, getting nearly $178m in damages and future royalties.

Researchers Coax Secrets, Possible Drug Targets From Multiple Myeloma Genome

The whole genome study suggests new targets for the incurable bone-marrow cancer, but even the nearest at hand could be years away from producing a therapeutic agent.

Researchers Coax Secrets, Possible Drug Targets From Multiple Myeloma Genome

The whole genome study suggests new targets for the incurable bone-marrow cancer, but even the nearest at hand could be years away from producing a therapeutic agent.

Related Content

Topics

UsernamePublicRestriction

Register

PS071794

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel